Skip to main
NPCE
NPCE logo

NeuroPace (NPCE) Stock Forecast & Price Target

NeuroPace (NPCE) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NeuroPace Inc. has demonstrated substantial improvement in patient quality of life, as shown by a significant mean increase of 3.2 points on the QOLIE-89 survey following one year of treatment with the RNS system. The company's revenue growth has been robust, with a notable inflection seen in 2022, projecting a remarkable increase of 75.5% from 2022 to 2024. Furthermore, favorable macro trends, including a rise in the number of Comprehensive Epilepsy Centers and a 150% increase in epileptologists per capita from 2012 to 2019, indicate an expanding market and increasing awareness, which could drive further adoption of the RNS system.

Bears say

NeuroPace Inc. has been experiencing significant net losses and anticipates continued financial strain, with no clear path to achieving profitability in the near term. The necessity for additional capital to sustain operations presents challenges, as obtaining funding may prove difficult and could lead to unfavorable terms that impact business operations negatively. Furthermore, existing financial obligations and uncertainties regarding future guidance, along with competitive risks and potential dilution, exacerbate the company's precarious financial condition, contributing to a negative outlook on its stock performance.

NeuroPace (NPCE) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeuroPace and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeuroPace (NPCE) Forecast

Analysts have given NeuroPace (NPCE) a Buy based on their latest research and market trends.

According to 5 analysts, NeuroPace (NPCE) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeuroPace (NPCE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.